Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Correction: Cortical microstructure in primary progressive aphasia: a multicenter study. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Alzheimers Res Ther 2023
    PMID:36739431

  2. Amyloid Precursor Protein 𝛽CTF accumulates in synapses in sporadic and genetic forms of Alzheimer's disease. Ferrer-Raventós, P, Puertollano-Martín, D, Querol-Vilaseca, M et al. Neuropathol Appl Neurobiol 2023
    PMID:36702749

  3. Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks. Zhang, Y, Ghose, U, Buckley, NJ et al. Front Aging Neurosci 2022
    PMID:36523958

  4. Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis. de Luna, N, Carbayo, Á, Dols-Icardo, O et al. Neurol Neuroimmunol Neuroinflamm 2023
    PMID:36460480

  5. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. Holstege, H, Hulsman, M, Charbonnier, C et al. Nat Genet 2022
    PMID:36411364

  6. Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients. Lennol, MP, Sánchez-Domínguez, I, Cuchillo-Ibañez, I et al. Alzheimers Res Ther 2022
    PMID:36324176

  7. Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders. Gómez de San José, N, Goossens, J, Al Shweiki, MR et al. J Psychiatr Res 2022
    PMID:36323141

  8. Early Motor Changes in Genetic Frontotemporal Dementia. Lleó, A, Illán-Gala, I Neurology 2022
    PMID:36219793

  9. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease. Villarejo-Galende, A, García-Arcelay, E, Piñol-Ripoll, G et al. J Alzheimers Dis 2022
    PMID:36155523

  10. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. Jansen, IE, van der Lee, SJ, Gomez-Fonseca, D et al. Acta Neuropathol 2022
    PMID:36066633

  11. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease. Benejam, B, Aranha, MR, Videla, L et al. Alzheimers Res Ther 2022
    PMID:36057615

  12. Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Valle-Tamayo, N, Pérez-González, R, Chiva-Blanch, G et al. J Vis Exp 2022
    PMID:35993755

  13. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome. Videla, L, Benejam, B, Pegueroles, J et al. JAMA Netw Open 2022
    PMID:35930282

  14. The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary. Hampel, H, Elhage, A, Shaw, LM et al. Neurodegener Dis Manag 2022
    PMID:35866715

  15. Intermediate and Expanded HTT Alleles and the Risk for α-Synucleinopathies. Pérez-Oliveira, S, Álvarez, I, Rosas, I et al. Mov Disord 2022
    PMID:35852957

Search PubMed